Risk of Gastrointestinal Events During Vandetanib Therapy in Patients With Cancer: A Systematic Review and Meta-analysis of Clinical Trials

Yang, Xiongwen; Xiong, Peng; Cheng, Xiaoshu; Kuang, Yi; Cheng, Yingzhang

doi:10.1097/mjt.0000000000000306

Cited by 3 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent meta-analysis evaluated the relative risk and incidence of vandetanib-associated gastrointestinal AEs in 22 trials with 6382 patients with cancer. The incidences of all-grade gastrointestinal AEs were anorexia 24%, constipation 17%, diarrhea 46%, nausea 29%, and vomiting 17% 66…”

Section: Adverse Eventsmentioning

confidence: 99%

<p>Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes</p>

Fallahi¹,

Ferrari²,

Elia³

et al. 2019

CMAR

View full text Add to dashboard Cite

Medullary thyroid cancers (MTCs) are neuroendocrine tumors, which secrete calcitonin and carcinoembryonic antigen, both of which can serve as tumor markers. Extensive and accurate surgical resection is the primary treatment for MTC, whereas the use of external beam radiotherapy is limited. Moreover, since MTC is derived from thyroid parafollicular cells or C cells, it is not responsive to either radioiodine or thyroid-stimulating hormone suppression, and therefore, they cannot be considered as treatment strategies. Traditional therapies for advanced or metastatic progressive medullary thyroid cancer (pMTC) are poorly effective. Among the new approaches tested in clinical trials, targeted chemotherapies with tyrosine kinase inhibitors (TKIs) are now available and they represent effective interventions for progressive disease, with additional investigational options emerging. This paper reviews the efficacy and safety of vandetanib in patients with a pMTC, as it has been shown to improve progression-free survival (30.5 vs 19.3 months in controls). Vandetanib is approved by the FDA and EMA for symptomatic or progressive MTC in patients with unresectable locally advanced or metastatic disease in adults, adolescents, and children older than 5 years. The most common adverse events in vandetanib-treated patients are diarrhea, rash, folliculitis, nausea, QTc prolongation, hypertension, and fatigue. More data are required to deepen our knowledge on molecular biology of tumor and host defense, with the aim to achieve better prognosis and higher quality of life for affected patients.

show abstract

Section: Adverse Eventsmentioning

confidence: 99%

<p>Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes</p>

Fallahi¹,

Ferrari²,

Elia³

et al. 2019

CMAR

View full text Add to dashboard Cite

show abstract

“…A recent meta-analysis has evaluated the relative risk and incidence of gastrointestinal AEs during vandetanib in patients with cancer. Twenty-two trials with 6382 patients were evaluated, summarizing incidences of all-grade gastrointestinal AEs in patients with cancer were anorexia 24%, constipation 17%, diarrhea 46%, nausea 29%, and vomiting 17% [66].…”

Section: Gastrointestinal Aesmentioning

confidence: 99%

The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer

Fallahi

Ferrari

Baldini

et al. 2016

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Traditional therapies for advanced or metastatic progressive medullary thyroid cancer (pMTC) are poor effective. Several TKIs have been tested in clinical trials in pMTC patients. Areas covered: This paper reviews efficacy and safety of vandetanib in the treatment of pMTC. Expert commentary: Vandetanib (trade name CAPRELSA® [Vandetanib]) has been shown to improve progression-free survival (30.5 vs 19.3 months in controls) in pMTC patients. Vandetanib is approved by FDA and EMA for metastatic MTC in adults; in adolescents and children with metastatic or locally advanced MTC, vandetanib seems to be effective. The most common adverse events in vandetanib-treated patients are: diarrhea, rash, folliculitis, nausea, QTc prolongation, hypertension and fatigue. In patients with aggressive differentiated thyroid cancer, vandetanib has shown promising results. Further research is needed to determine the ideal targeted therapy, based on tumor molecular characterization and host factors, to obtain the best response in terms of survival and quality of life.

show abstract

Antitumoral Agent-Induced Constipation: A Systematic Review

Calsina-Berna,

González-Barboteo,

Llorens-Torromé

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: Constipation is a common symptom in patients receiving antitumoral treatment. The mechanisms underlying antitumoral agent-induced constipation (ATAIC) are poorly defined. This systematic review aimed to analyze and synthesize the available information related to the prevalence, etiology, and treatment of ATAIC. Methods: A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines was conducted. The review included human studies written in English, French, or Spanish involving patients with cancer and containing information about the prevalence, etiology, and treatment of ATAIC. Results: A total of 73 articles were included. The reported prevalence ranged from 0.8% to 86.6%. Six studies reported an ATAIC prevalence of over 50%. The prevalence rates of constipation of grades 3 and 4 ranged between 0 and 11%. The importance of enteric neuronal integrity in gastrointestinal function was reported. The articles with the highest levels of evidence in relation to ATAIC treatment obtained in this systematic review studied treatments with acupuncture, sweet potato, osteopath, probiotics, and moxibustion. Conclusions: The prevalence of constipation in patients undergoing antitumoral treatment is very diverse. Studies specifically designed to report the prevalence of antineoplastic treatment-induced constipation are needed. The importance of enteric neuronal integrity in gastrointestinal function was described. Thus, neuroprotection could be an area of research for the treatment of chemotherapy-induced gastrointestinal disorders.

show abstract

Risk of Gastrointestinal Events During Vandetanib Therapy in Patients With Cancer: A Systematic Review and Meta-analysis of Clinical Trials

Cited by 3 publications

References 34 publications

<p>Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes</p>

<p>Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes</p>

The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer

Antitumoral Agent-Induced Constipation: A Systematic Review

Contact Info

Product

Resources

About